Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996, 335: 1785-1791. 10.1056/NEJM199612123352401.
Article
CAS
PubMed
Google Scholar
Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998, 16: 2038-2044.
CAS
PubMed
Google Scholar
Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol. 1999, 17: 846-854.
CAS
PubMed
Google Scholar
Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001, 7: 377-387.
CAS
PubMed
Google Scholar
Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ: Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003, 98: 1735-1744. 10.1002/cncr.11701.
Article
CAS
PubMed
Google Scholar
Rosen LS, Gordon DH, Dugan WJ, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE: Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004, 100: 36-43. 10.1002/cncr.11892.
Article
CAS
PubMed
Google Scholar
Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005, 23: 3314-3321. 10.1200/JCO.2005.05.116.
Article
CAS
PubMed
Google Scholar
Pavlakis N, Stockler M: Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2002, CD003474-
Google Scholar
Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003, 21: 4042-4057. 10.1200/JCO.2003.08.017.
Article
CAS
PubMed
Google Scholar
Verma S, Kerr-Cresswell D, Dranitsaris G, Charbonneau F, Trudeau M, Yogendran G, Cesta AM, Clemons M: Bisphosphonate use for the management of breast cancer patients with bone metastases: A survey of Canadian Medical Oncologists. Support Care Cancer. 2004, 12: 852-858. 10.1007/s00520-004-0671-9.
Article
PubMed
Google Scholar
Hillner BE, Weeks JC, Desch CE, Smith TJ: Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 2000, 18: 72-79.
CAS
PubMed
Google Scholar
Body JJ: Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer. 2003, 97: 859-865. 10.1002/cncr.11139.
Article
PubMed
Google Scholar
Clemons M, Enright K, Cesta A, Charbonneau F, Chow E, Warr D, Kee-Cresswell D, Chang J, Yogendran G, Trudeau M, De Angelis C, Cottrell W, Dranitsaris G: Do physicians follow systemic treatment and funding policy guidelines?. Can J Clin Pharmacol. 2004, 11: e168-78.
PubMed
Google Scholar
Enright K, Clemons M, Chow E: Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates-Toronto Sunnybrook Regional Cancer Centre experience. Support Care Cancer. 2004, 12: 48-52. 10.1007/s00520-003-0548-3.
Article
PubMed
Google Scholar
Coleman R, Rubens R: The clinical course of bone metastases from breast cancer. British Journal of Cancer. 1987, 55: 61-66.
Article
CAS
PubMed
PubMed Central
Google Scholar
Coleman RE: Skeletal complications of malignancy. Cancer. 1997, 80: 1588-1594. 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G.
Article
CAS
PubMed
Google Scholar
Plunkett TA, Smith P, Rubens RD: Risk of complications from bone metastases in breast cancer. implications for management. Eur J Cancer. 2000, 36: 476-482. 10.1016/S0959-8049(99)00331-7.
Article
CAS
PubMed
Google Scholar
Cook RJ, Lawless JF: Interim monitoring of longitudinal comparative studies with recurrent event responses. Biometrics. 1996, 52: 1311-1323.
Article
CAS
PubMed
Google Scholar
Ghosh D, Lin DY: Nonparametric analysis of recurrent events and death. Biometrics. 2000, 56: 554-562. 10.1111/j.0006-341X.2000.00554.x.
Article
CAS
PubMed
Google Scholar
Major PP, Cook R: Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol. 2002, 25: S10-8. 10.1097/00000421-200212001-00003.
Article
PubMed
Google Scholar
Coleman RE: Bisphosphonates: clinical experience. Oncologist. 2004, 9: 14-27. 10.1634/theoncologist.9-90004-14.
Article
CAS
PubMed
Google Scholar